UnitedHealth’s bid for DaVita Medical gets conditional FTC approval
Category: #health  By Mateen Dalal  Date: 2019-06-21
  • share
  • Twitter
  • Facebook
  • LinkedIn

UnitedHealth’s bid for DaVita Medical gets conditional FTC approval

Within forty days of closure of the acquisition, UnitedHealth Group would divest DaVita Medical Group’s healthcare provider in Las Vegas

UnitedHealth Group has reportedly been granted approval by the Federal Trade Commission for its $4.3 billion acquisition of DaVita Medical Group from DaVita Inc., following a lengthy regulatory procedure due to certain concerns regarding a monopoly in Las Vegas.

Apparently, the deal has had closer inspection from regulators than predicted. FTC's approval, announced on the afternoon of June 19, 2019, came with conditions including divestitures of a Las Vegas health plan network under a consent order with the government and a proposed antitrust settlement.

The FTC has stated that within forty days of closure of the acquisition, UnitedHealth Group would divest DaVita Medical Group’s healthcare provider agency in Las Vegas, called HealthCare Partners of Nevada, to Utah-based healthcare provider Intermountain HealthCare. The FTC seemed worried about a monopoly in Las Vegas, stating that UnitedHealth's Optum providers and operations under the ownership of DaVita would have ruled majority of the market.

According to reports, UnitedHealth’s Optum confirmed the acquisition and announced that DaVita’s high-quality practices in Washington, Florida, California, Colorado and New Mexico are now under OptumCare.

Andrew Witty, CEO, Optum, was reportedly quoted saying that it was an important step in building a next-gen healthcare organization and improving patient healthcare experiences while lowering costs across the entire range of healthcare services, including primary, specialty, urgent, and surgical care.

For the uninitiated, DaVita Medical Group is a subsidiary of DaVita Inc., which is an major provider of dialysis and kidney care services. UnitedHealth will not be possessing DaVita’s kidney care centers. The range of DaVita operations sold to Optum include centers for surgery and urgent care, along with medical clinics governed by both primary care doctors and specialists.  

UnitedHealth Group is a Minnesota-based managed health care brand that offers health care products and insurance services. The brand Optum was established in 2011 in order to affiliate the company's healthcare services business.

 

Source credit: https://www.forbes.com/sites/brucejapsen/2019/06/19/unitedhealth-group-wins-ftc-approval-of-davita-deal/#49797f846e40

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

AbbVie buys Mavupharma to target STING pathway for cancer treatment
AbbVie buys Mavupharma to target STING pathway for cancer treatment
By Mateen Dalal

AbbVie Inc., a US-based pharmaceutical company recently announced acquisition of Mavupharma, a Seattle-based biopharmaceutical company, which is focused on innovative strategies to target the STimulator of INterferon Genes pathway for the treatment o...

Motorola Solutions buys WatchGuard to expand video security portfolio
Motorola Solutions buys WatchGuard to expand video security portfolio
By Mateen Dalal

WatchGuard’s solutions allow law enforcement users to manage high-quality video evidence Motorola Solutions, Inc., the US based data communications and telecommunications equipment provider, has recently announced the acquisition of WatchGuard...

Cara begins Phase 2 trial of pruritus treatment in dermatitis patients
Cara begins Phase 2 trial of pruritus treatment in dermatitis patients
By Mateen Dalal

The study is formulated to evaluate the safety and efficacy of Oral KORSUVA for moderate to severe pruritus Biopharmaceutical firm Cara Therapeutics Inc. has reportedly announced the initiation of their Phase 2 trial of Oral KORSUVATM for pruritus t...